BioAlliance Pharma (BIO)

Business description

BioAlliance Pharma is a French drug development company focused on orphan cancer and supportive care treatments. It has two FDA-approved specialty products and three clinical-stage orphan oncology candidates.

Share price chart

Share chart

Stock data

Market cap.€157.8m
Last close€7.630
High / Low (52 weeks)€10.5 / €3.8
Stock market listingEuronext Paris
Forecast net debt (€m)2.7
Forecast gearing ratio (%)41
SectorPharmaceutical & Healthcare

Price performance

Relative *(0.8)(1.8)81.2

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Pharmaceuticals Acorda Therapeutics
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
AmpliPhi Biosciences Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Arena Pharmaceuticals Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Astex Pharmaceuticals
Athersys AVEO Pharmaceuticals
Avita Medical Basilea
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MolMed
Mologen AG MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onyx Pharmaceuticals
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prima BioMed
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Regeneus ReNeuron Group
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB uniQure NV
United Drug Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Xencor Zealand Pharma
Zeltia Ziopharm Oncology
Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2012A 4.0 (11.9) (11.6) (65.44) N/A N/A
2013A 1.5 (15.8) (15.3) (74.12) N/A N/A
2014E 2.4 (14.8) (14.3) (69.32) N/A N/A
2015E 4.0 (14.5) (15.6) (75.43) N/A N/A

Last updated on 23/07/2014

Investment summary

The imminent BioAlliance/Topotarget merger to create Onxeo to focus on orphan oncology brings together three late-stage assets: Validive and Livatag from BioAlliance and Beleodaq from Topotarget. The strategy is to commercialise these alone in Europe, leveraging the commercial base, with first launches from 2017e. Near-term catalysts include Beleodaq US launch in coming months, Livatag further safety assessments (November) and Validive Phase II data (Q414). Our standalone BioAlliance valuation is increased to €187m. Our initial estimates suggest Onxeo could be worth €284m, including Beleodaq in peripheral T-cell lymphoma (PTCL) only.

Last updated on 23/07/2014

Industry outlook

The proposed merger could complete in July/August 2014 subject to EGM approvals and would result in Topotarget shareholders owning c 1/3 of the combined entity, with existing BioAlliance shareholders holding c 2/3. The proposed strategy is to market the orphan oncology products alone in Europe, with three complementary products providing sales & marketing synergies.

Last updated on 30/06/2014

Key management

Judith Greciet, CEO
Nicolas Fellmann, CFO
Pierre Attali, COO

Company address

49 Boulevard du Général Matrial Valin
+33 (0)1 45 58 71 00
View website